Equine herpesvirus vaccine

Abstract

A vaccine for protecting a horse against diseases associated with EHV-1 and/or EHV-4 is provided. The vaccine commonly includes inactivated EHV-1 (e.g., chemically inactivated EHV-1 KyA virus) and an adjuvant. The adjuvant can include a cross-linked olefinically unsaturated carboxylic acid polymer which may have bioadhesive properties. The vaccine may also include antigens against other equine pathogens such as inactivated EHV-4 and inactivated A1 and/or A2 strains of equine influenza virus. Methods for protecting horses against diseases associated with EHV-1 and/or EHV-4 and methods of producing the equine herpesvirus vaccine are also provided.

1 . A vaccine for protecting a horse against diseases associated with EHV-1, EHV-4 or a combination thereof comprising: 
 chemically inactivated EHV-1 KyA virus; and    an adjuvant.    
   
   
       2 . A method of producing an equine herpesvirus vaccine comprising: 
 (a) inoculating simian cells with an EHV-1 KyA virus;    (b) incubating the inoculated simian cells;    (c) harvesting EHV-1 KyA virus from the incubated cells; and    (d) treating the harvested cells with a chemical inactivating agent which includes a compound selected from the group consisting of ethylenimine, binary ethylenimine, acetylethylenimine or a mixture thereof to form inactivated EHV-1 KyA virus.    
   
   
       3 . A kit for detecting EHV-1 and EHV-4 in a test sample comprising: 
 (a) a first monoclonal antibody that immunoreacts with EHV-1 to form a first complex;    (b) a second monoclonal antibody that immunoreacts with EHV-4 to form a second complex; and    (c) at least one detectable label for use in detecting the first complex, the second complex, or both complexes.